Colonic Diseases Clinical Trial
Official title:
Facilitation of Early Mobilization After Colorectal Surgery: A Randomized Controlled Trial
Verified date | March 2018 |
Source | McGill University Health Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Early mobilization (i.e. initiation of out of bed activities from the day of surgery) is considered an important component of postoperative care after colorectal surgery. Having a health professional dedicated to facilitate early mobilization has the potential to enhance postoperative recovery by preventing the negative effects of prolonged bed rest (e.g. increased risk for complications, muscle loss, deconditioning and functional decline); however, the need to implement this resource-intensive approach is not evidence based. This study aims to contribute evidence about the role of facilitated early mobilization as a strategy to enhance recovery after colorectal surgery.
Status | Completed |
Enrollment | 100 |
Est. completion date | May 2016 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult people (>18 years) - Colonic or rectal diseases (i.e. cancer, inflammatory bowel disease, diverticulitis) planned for surgical resection Exclusion Criteria: - Metastatic disease - Medical conditions that preclude postoperative mobilization (e.g. neurological or musculoskeletal diseases) - Inability to understand English or French - Admission to intensive care immediately after the surgery |
Country | Name | City | State |
---|---|---|---|
Canada | Montreal General Hospital | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
McGill University Health Center | Mitacs |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional walking capacity (six-minute walk test) | The outcome of interest will be the proportion of participants returning to preoperative levels of functional walking capacity at 4 weeks after surgery (within an estimated measurement error of 20 meters) | before surgery; 4 weeks after surgery | |
Secondary | Time out of bed (sitting and standing) | Measured by an activity monitor (Actigraph) worn over the participants' hip | postoperative day (POD) 0, 1, 2 and 3 | |
Secondary | Time to readiness for discharge | Time to achieve standardized hospital discharge criteria (tolerance of oral intake, recovery of lower gastrointestinal function, adequate pain control on oral analgesia, ability to mobilize and self care and no evidence of complications or untreated medical problems). | duration of hospital stay (expected average of 3 days after surgery) | |
Secondary | Time to recovery of gastrointestinal motility | Time to achieve criteria for recovery of gastrointestinal transit (tolerance of solid diet and bowel movement) | Expected average of 2 days after surgery | |
Secondary | Postoperative fatigue (Multidimensional Fatigue Inventory) | before surgery; POD 1, 2 and 3; 2 weeks after surgery; 4 weeks after surgery. | ||
Secondary | Self-reported physical activity status (Duke Activity Status Index) | before surgery; 2 weeks after surgery; 4 weeks after surgery | ||
Secondary | Mobility (Life-Space Mobility Assessment) | before surgery; 4 weeks after surgery | ||
Secondary | Condition-specific health-related quality of life (Abdominal Surgery Impact Scale) | before surgery; POD 1, 2 and 3; 2 weeks after surgery; 4 weeks after surgery | ||
Secondary | Generic heath-related quality of life (RAND-36) | before surgery; 4 weeks after surgery | ||
Secondary | Postoperative complications | Classified according to Clavien-Dindo Index and converted into a continuous scale using the Comprehensive Complication Index | up to 4 weeks after surgery | |
Secondary | Pulmonary function (spirometry) | Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and cough expiratory flow (CEF) will be recorded | before surgery; POD 1, 2 and 3; 4 weeks after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Terminated |
NCT01119027 -
Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills
|
N/A | |
Completed |
NCT01063231 -
Evaluation of PillCamâ„¢ Colon 2 in Visualization of the Colon
|
Phase 3 | |
Completed |
NCT04074577 -
Computer Aided Detection, Tandem Colonoscopy Study
|
N/A | |
Not yet recruiting |
NCT04087824 -
Deep Learning Algorithm for Recognition of Colonic Segments.
|
N/A | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT02503631 -
Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
|
||
Completed |
NCT01600209 -
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
|
N/A | |
Completed |
NCT01260168 -
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
|
N/A | |
Completed |
NCT00604162 -
PillCamâ„¢ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon
|
Phase 3 | |
Recruiting |
NCT04598880 -
Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing
|
Phase 4 | |
Completed |
NCT01738425 -
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04080843 -
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
|
Phase 2 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Completed |
NCT02291445 -
Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study
|
Phase 2 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03139942 -
Optical Polyp Testing for In Vivo Classification
|
N/A | |
Completed |
NCT04263818 -
Endoscopist and Endoscope Motions During Colonoscopy
|
N/A | |
Recruiting |
NCT05923918 -
A Study to Evaluate Safety and Efficacy of PBK_M2101
|
Phase 3 | |
Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 |